Cognitive effects of pregabalin in healthy volunteers: A double-blind, placebo-controlled trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antiepileptic drugs (AEDs) can be associated with neurotoxic side effects including cognitive dysfunction, a problem of considerable importance given the usual long-term course of treatment. Pregabalin is a relatively new AED widely used for the treatment of seizures and some types of chronic pain including fibromyalgia. We measured the cognitive effects of 12 weeks of pregabalin in healthy volunteers. METHODS: Thirty-two healthy volunteers were randomized in a double-blind parallel study to receive pregabalin or placebo (1:1). Pregabalin was titrated over 8 weeks to 600 mg/d. At baseline, and after 12 weeks of treatment, all subjects underwent cognitive testing. Test-retest changes in all cognitive and subjective measures were Z scored against test-retest regressions previously developed from 90 healthy volunteers. Z scores from the placebo and pregabalin groups were compared using Wilcoxon tests. RESULTS: Thirty subjects completed the study (94%). Three of 6 target cognitive measures (Digit Symbol, Stroop, Controlled Oral Word Association) revealed significant test-retest differences between the pregabalin and placebo groups, all showing negative effects with pregabalin (p < 0.05). These cognitive effects were paralleled by complaints on the Portland Neurotoxicity Scale, a subjective measure of neurotoxicity (p < 0.01). CONCLUSION: At conventional doses and titration, pregabalin induced mild negative cognitive effects and neurotoxicity complaints in healthy volunteers. These effects are one factor to be considered in the selection and monitoring of chronic AED therapy. Class of Evidence: This study provides Class I evidence that pregabalin 300 mg BID negatively impacts cognition on some tasks in healthy volunteers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Wechsler Adult Intelligence Scale--Third Edition
Wechsler, D. (2019) · PsycTESTS Dataset · doi:10.1037/t49755-000 · Cited by 2,327
Cited by
The effect of pain on cognitive function: A review of clinical and preclinical research
Moriarty, O., McGuire, B. E., & Finn, D. P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.002 · Cited by 1,122
Skvarc, D. R., Berk, M., Byrne, L. K., Dean, O. M., Dodd, S., Lewis, M., Marriott, A., Moore, E. M., Morris, G., Page, R. S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.011 · Cited by 312
Stahl, S. M., Porreca, F., Taylor, C. P., Cheung, R., Thorpe, A. J., & Clair, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.001 · Cited by 277
Cognitive Impairment in Fibromyalgia
Bertolucci, P. H. F., & Oliveira, F. F. (2013) · Current Pain and Headache Reports · doi:10.1007/s11916-013-0344-9 · Cited by 62
“A recent study provided Class I evidence that, during a 12-week treatment with full therapeutic doses (up to 300 mg twice daily) for healthy volunteers, pregabalin had significant negative cognitive effects as measured by way of the Digit Symbol Test, the Stroop Color-Word Test, and the Controlled Oral Word Associatio…”
MethodThe Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia
Mohs, R., Mease, P., Arnold, L. M., Wang, F., Ahl, J., Gaynor, P. J., & Wohlreich, M. M. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31825b9855 · Cited by 23
Metadata
- Authors
- Salinsky, M., Storzbach, D., & Munoz, S.
- Venue
- Neurology
- Published
- 2010-03-02
- Volume
- 74
- Issue
- 9
- Pages
- 755-761
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2118563553
- Cited by
- 74
- References
- 2
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive effects of pregabalin in healthy volunteers: A double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181d25b34
- The paper
- Salinsky, M., Storzbach, D., & Munoz, S. (2010). Cognitive effects of pregabalin in healthy volunteers: A double-blind, placebo-controlled trial. Neurology. https://doi.org/10.1212/wnl.0b013e3181d25b34
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.